BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rothschild SI, Betticher D, Zenhäusern R, Anchisi S, von Moos R, Pless M, Moosmann P, Popescu RA, Calderoni A, Dressler M, Rauch D, Pederiva S, Woelky R, Papet C, Bühler V, Borner M. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer Chemother Pharmacol 2019;84:881-9. [PMID: 31444619 DOI: 10.1007/s00280-019-03927-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Gorji M, Joseph J, Pavlakis N, Smith SD. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis. Asia Pac J Clin Oncol 2022. [PMID: 35352492 DOI: 10.1111/ajco.13740] [Reference Citation Analysis]
2 Mihai MM, Ion A, Giurcăneanu C, Nițipir C, Popa AM, Chifiriuc MC, Popa MI, Říčař J, Popa LG, Sârbu I, Lazăr V. The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients. J Clin Med 2021;10:3219. [PMID: 34362003 DOI: 10.3390/jcm10153219] [Reference Citation Analysis]
3 Lugtenberg RT, Boers-Doets CB, Witteveen PO, van Herpen CML, Wymenga ANM, de Groot JWB, Hoeben A, Del Grande C, van Doorn B, Koldenhof JJ, Driessen CML, Gelderblom H. Prospective practice survey of management of cetuximab-related skin reactions. Support Care Cancer 2021;29:3497-506. [PMID: 33150521 DOI: 10.1007/s00520-020-05862-7] [Reference Citation Analysis]
4 Taira K, Fujiwara K, Fukuhara T, Morisaki T, Koyama S, Donishi R, Takeuchi H. Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report. Yonago Acta Med 2020;63:379-84. [PMID: 33253347 DOI: 10.33160/yam.2020.11.020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]